Insider filings
Biotechnology, listed on NASDAQ.
Free on iOS and Android
EarningsQ3 FY2026 · reported Nov 5, 2026
10x Genomics beat by 1.8% on revenue.
Revenue $151M against a $148M consensus. EPS was -$0.15 a share under GAAP; the -$0.27 consensus is for adjusted EPS.
Revenue
Beat 5Miss 1
EPS against the consensus, quarter by quarter. Outlined: a GAAP figure against an adjusted consensus.
Next report Feb 11, 2027. Consensus -$0.23 a share.
Every quarterMoney managers13F filings for Jun 30, 2026
institutions reported 10x Genomics shares in 13F filings for Jun 30, 2026. FMR LLC held the largest stake, $675.9M.
Insider tradesForm 4 · 8 open-market filings shown
Eight open-market sales, 4 of them under 10b5‑1 plans.
Aug 24, 2026Sep 22, 2026
SalesSales under a plan
A median 2 business days from trade to filing. Form 4 is due within two.
Every filing| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q3 FY2026reported Nov 5, 2026 | -$0.15 | -$0.27 | $150.7M | $148.0M | EPS beat, GAAPRevenue beat |
| Q2 FY2026reported Aug 6, 2026 | -$0.14 | -$0.24 | $151.0M | $146.7M | EPS beat, GAAPRevenue beat |
| Q1 FY2026reported May 7, 2026 | -$0.10 | -$0.29 | $150.8M | $146.4M | EPS beat, GAAPRevenue beat |
| Q4 FY2025reported Feb 12, 2026 | -$0.13 | -$0.19 | $166.0M | $159.7M | EPS beatRevenue beat |
| Q3 FY2025reported Nov 6, 2025 | -$0.22 | -$0.07 | $149.0M | $142.5M | EPS miss, GAAPRevenue beat |
| Q2 FY2025reported Aug 7, 2025 | $0.28 | -$0.35 | $172.9M | $139.5M | EPS beat, GAAPRevenue beat |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Past year Each firm's latest target, newest first
| Firm | Rating | Target | Action | Date |
|---|---|---|---|---|
| UBS | Neutral | $61 | Target set | |
| Stifel | Buy | $68 | Target set |
Each firm's latest target from the past year, with the rating stated with its note. These are the firms' own views, not GetSignal's, and we do not endorse them. Not investment advice.
8 other firms rated TXG in the past year with no current target listed here. Ratings and targets come from licensed market data providers. A target is listed only after its firm and company are confirmed against a report of the note. As of Nov 9, 2026.
| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Serge SaxonovChief Executive Officer | $674K | $5.0M | $635K | $6.3M |
| Benjamin J. HindsonPresident and Chief Scientific Officer | $519K | $1.8M | $293K | $2.6M |
| Adam S. TaichChief Financial Officer | $507K | $1.4M | $285K | $2.2M |
The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. 1 executive who has since left the company is named in that filing and not shown here. Read the filing
| Holder | Value | Shares | Shares vs prior qtr | % of shares out |
|---|---|---|---|---|
| FMR LLC | $675.9M | 17,629,266 | -0.6% | 13.56% |
| BlackRock, Inc. | $414.2M | 10,804,070 | +7.2% | 8.31% |
| ARK Investment Management LLCCathie Wood | $383.5M | 10,003,057 | -14.6% | 7.70% |
| Vanguard Portfolio Management LLC | $267.7M | 6,982,492 | +1.0% | 5.37% |
| Quantinno Capital Management LP | $209.7M | 5,469,698 | +1.1% | 4.21% |
| Vanguard Capital Management LLC | $194.9M | 5,082,594 | -3.5% | 3.91% |
| T. Rowe Price Associates, Inc. | $174.0M | 4,539,007 | +2681.0% | 3.49% |
| Sumitomo Mitsui Trust Group, Inc. | $160.8M | 4,194,627 | -17.9% | 3.23% |
| Amova Asset Management Americas, Inc. | $160.7M | 4,192,517 | -17.9% | 3.23% |
| Morgan Stanley | $128.5M | 3,351,911 | +26.2% | 2.58% |
| Goldman Sachs Group Inc | $120.7M | 3,148,859 | -20.7% | 2.42% |
| Geode Capital Management, LLC | $118.2M | 3,082,790 | +6.1% | 2.37% |
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
| Insider | Action | Shares | Price | Value | Trade date | Delay (business days) |
|---|---|---|---|---|---|---|
| Serge SaxonovChief Executive Officer | Sold · scheduled · 5 lines | 25,000 | $81.22 | $2.0M | Sep 22, 2026filed Sep 24, 2026 | 2d |
| Shehnaaz SulimanDirector | Sold · scheduled · 5 lines | 5,723 | $81.19 | $465K | Sep 22, 2026filed Sep 24, 2026 | 2d |
| Adam TaichChief Financial Officer | Sold · scheduled · 3 lines | 46,388 | $64.57 | $3.0M | Sep 9, 2026filed Sep 11, 2026 | 2d |
| John R. StuelpnagelDirector | Sold · 3 lines | 20,000 | $61.75 | $1.2M | Sep 3, 2026filed Sep 8, 2026 | 2d |
| Serge SaxonovChief Executive Officer | Sold · scheduled · 3 lines | 10,486 | $63.69 | $668K | Aug 26, 2026filed Aug 28, 2026 | 2d |
| Benjamin J. HindsonDirector | Sold | 13,818 | $63.02 | $871K | Aug 24, 2026filed Aug 26, 2026 | 2d |
| Adam TaichChief Financial Officer | Sold | 17,166 | $63.02 | $1.1M | Aug 24, 2026filed Aug 26, 2026 | 2d |
| Serge SaxonovChief Executive Officer | Sold | 18,545 | $63.02 | $1.2M | Aug 24, 2026filed Aug 26, 2026 | 2d |
One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. Scheduled: set up in advance under a Rule 10b5-1 trading plan. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.
| Insider | Event | Shares | Date |
|---|---|---|---|
| Serge SaxonovChief Executive Officer | Gift | 100 | Sep 1, 2026 |
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
On Form 4, code P is an open-market purchase and S an open-market sale; a sale marked scheduled was set up in advance under a Rule 10b5-1 plan. Awards, option exercises, tax withholding and gifts (A, M, F and G) are listed under Other Form 4 activity and never counted as either.
Data as of Nov 9, 2026.
What the filings on TXG show and how current they are.
Across the 8 most recent open-market filings shown here, 0 were purchases and 8 were sales. 4 were scheduled in advance under a Rule 10b5-1 plan.
Insider filings on this page reached the public a median of 2 business days after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows.
